CIP2A and neoplasm: Among patients with pT2 tumours, however, 5-year survival of CIP2A strongly positive patients was 28.6% (95% CI 0–62.0) compared with 66.7% (95% CI 35.9–97.5) for those with low CIP2A expression (logrank test, P=0.018; Figure 2D).